Patents by Inventor Jill A. Livengood

Jill A. Livengood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for inactivating zika virus and for determining the completeness of inactivation
    Patent number: 11964008
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: April 23, 2024
    Assignee: Takeda Vaccines, Inc.
    Inventors: Jill A. Livengood, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford, Sushma Kommareddy
  • Compositions and methods for dengue virus chimeric constructions in vaccines
    Patent number: 11931399
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Grant
    Filed: December 12, 2022
    Date of Patent: March 19, 2024
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
  • METHOD FOR INACTIVATING ZIKA VIRUS AND RELATED METHODS
    Publication number: 20240024454
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation and to a method for determining the residual formaldehyde content in a pharmaceutical composition comprising an inactivated virus.
    Type: Application
    Filed: June 22, 2023
    Publication date: January 25, 2024
    Inventors: Jill A. LIVENGOOD, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford, Nao Ogasawara, Masafumi Misaki, Satoshi Adachi, Sushma Kommareddy
  • ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME
    Publication number: 20230414743
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.
    Type: Application
    Filed: June 16, 2023
    Publication date: December 28, 2023
    Inventors: Jill A. LIVENGOOD, Hansi DEAN, Htay Htay HAN, Raman RAO, Jackie MARKS, Gary DUBIN, Laurence DE MOERLOOZE, Hetal PATEL, Sushma KOMMAREDDY
  • ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME
    Publication number: 20230398199
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.
    Type: Application
    Filed: November 30, 2018
    Publication date: December 14, 2023
    Inventors: Jill A. LIVENGOOD, Hansi DEAN, Htay Htay HAN, Raman RAO, Jackie MARKS, Gary DUBIN, Laurence DE MOERLOOZE, Hetal PATEL, Asae SHINTANI, Holli GIEBLER, James GIFFORD, Mark LYONS, Sushma KOMMAREDDY, Tatsuki SATOU
  • Zika vaccines and immunogenic compositions, and methods of using the same
    Patent number: 11730802
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: August 22, 2023
    Assignee: Takeda Vaccines, Inc.
    Inventors: Jill A Livengood, Hansi Dean, Htay Htay Han, Raman Rao, Jackie Marks, Gary Dubin, Laurence De Moerlooze, Hetal Patel, Sushma Kommareddy
  • METHOD FOR DETERMINING THE POTENCY OF ANTIGENS
    Publication number: 20230204567
    Abstract: The present disclosure relates to a method for determining the potency of an antigen sample such as a vaccine antigen sample. The present disclosure is also related to a method for monitoring the potency of a vaccine antigen during the production process including purifying, inactivating and formulating the vaccine antigen and to a method for producing a virus vaccine. Further, the present disclosure relates to vaccines obtainable by the methods disclosed. In certain embodiments of the present invention the antigen sample is a zika virus antigen sample.
    Type: Application
    Filed: March 19, 2021
    Publication date: June 29, 2023
    Applicant: Takeda Vaccines, Inc.
    Inventors: Jill LIVENGOOD, Michael JOHNSON, James GIFFORD, Tawnya NEAD, Mark LYONS, Jackie MARKS
  • COMPOSITIONS AND METHODS FOR DENGUE VIRUS CHIMERIC CONSTRUCTIONS IN VACCINES
    Publication number: 20230181682
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Application
    Filed: December 12, 2022
    Publication date: June 15, 2023
    Applicants: TAKEDA VACCINES INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY
    Inventors: Dan T. STINCHCOMB, Claire KINNEY, Richard M. KINNEY, Jill A. LIVENGOOD
  • Zika vaccines and immunogenic compositions, and methods of using the same
    Patent number: 11648304
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of manufacture, formulation, testing, and uses thereof.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: May 16, 2023
    Assignee: Takeda Vaccines, Inc.
    Inventors: Jill A. Livengood, Holli Giebler, Whitney Baldwin, Hansi Dean, Claire Y. H. Kinney
  • METHOD FOR INACTIVATING ZIKA VIRUS AND FOR DETERMINING THE COMPLETENESS OF INACTIVATION
    Publication number: 20230145065
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.
    Type: Application
    Filed: September 13, 2022
    Publication date: May 11, 2023
    Applicant: TAKEDA VACCINES, INC.
    Inventors: Jill A. LIVENGOOD, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford, Sushma Kommareddy
  • Method for inactivating Zika virus and for determining the completeness of inactivation
    Patent number: 11478541
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: October 25, 2022
    Assignee: Takeda Vaccines, Inc.
    Inventors: Jill A. Livengood, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford
  • NOVEL ANTI-ZIKA VIRUS ANTIBODIES AND USES THEREOF
    Publication number: 20220332800
    Abstract: The present invention provides isolated monoclonal antibodies, or antigen-binding portions thereof, that bind to ZIKV glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies, or antigen-binding portions thereof, according to the present invention are useful for inhibiting or neutralizing ZIKV activity, thus providing a means of treating or preventing ZIKV infection in humans. The antibodies, or antigen-binding portions thereof, according to the present invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.
    Type: Application
    Filed: September 20, 2019
    Publication date: October 20, 2022
    Applicant: Takeda Vaccines, Inc.
    Inventors: Subash C. DAS, Isamu TSUJI, Jill A. LIVENGOOD, Hansi DEAN
  • Compositions and Methods for Dengue Virus Chimeric Constructions in Vaccines
    Publication number: 20220062375
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 3, 2022
    Applicants: TAKEDA VACCINES, INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT
    Inventors: Dan T. STINCHCOMB, Claire KINNEY, Richard M. KINNEY, Jill A. LIVENGOOD
  • METHOD FOR INACTIVATING ZIKA VIRUS AND RELATED METHODS
    Publication number: 20210403879
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation and to a method for determining the residual formaldehyde content in a pharmaceutical composition comprising an inactivated virus.
    Type: Application
    Filed: November 30, 2018
    Publication date: December 30, 2021
    Inventors: Jill A LIVENGOOD, Holli GIEBLER, Hansi DEAN, Tatsuki SATOU, Raman RAO, Jackie MARKS, Mark LYONS, Asae SHINTANI, James GIFFORD, Nao OGASAWARA, Masafumi MISAKI, Satoshi ADACHI
  • METHOD FOR INACTIVATING ZIKA VIRUS AND FOR DETERMINING THE COMPLETENESS OF INACTIVATION
    Publication number: 20210177959
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.
    Type: Application
    Filed: November 5, 2018
    Publication date: June 17, 2021
    Inventors: Jill A. LIVENGOOD, Holli GIEBLER, Hansi DEAN, Tatsuki SATOU, Raman RAO, Jackie MARKS, Mark LYONS, Asae SHINTANI, Jamie GIFFORD
  • ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME
    Publication number: 20210177958
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.
    Type: Application
    Filed: November 5, 2018
    Publication date: June 17, 2021
    Inventors: Jill A LIVENGOOD, Hansi DEAN, Htay Htay HAN, Raman RAO, Jackie MARKS, Gary DUBIN, Laurence DE MOERLOOZE, Hetal PATEL, Sushma KOMMAREDDY
  • ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME
    Publication number: 20210106669
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.
    Type: Application
    Filed: November 30, 2018
    Publication date: April 15, 2021
    Inventors: Jill A. LIVENGOOD, Hansi DEAN, Htay Htay HAN, Raman RAO, Jackie MARKS, Gary DUBIN, Laurence DE MOERLOOZE, Hetal PATEL
  • Compositions, methods and uses for dengue virus serotype-4 constructs
    Patent number: 10898565
    Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: January 26, 2021
    Assignees: Takeda Vaccines, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Jill A. Livengood, Claire Kinney, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
  • Zika Vaccines and Immunogenic Compositions, and Methods of Using the Same
    Publication number: 20200360505
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of manufacture, formulation, testing, and uses thereof.
    Type: Application
    Filed: November 5, 2018
    Publication date: November 19, 2020
    Inventors: Jill A. LIVENGOOD, Holli GIEBLER, Whitney BALDWIN, Hansi DEAN, Claire Y.H. KINNEY
  • Compositions and methods for live, attenuated alphavirus formulations
    Patent number: 10806781
    Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 20, 2020
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jill A. Livengood, Laszlo Varga